

STATEMENT BY THE NOMINATION COMMITTEE PRIOR TO THE EXTRAORDINARY GENERAL MEETING OF AFFIBODY AB (PUBL)

The establishment of the nomination committee

At the annual general meeting on 30 June 2021, it was resolved to adopt principles for the nomination of and instructions for the nomination committee of Affibody AB (publ) ("Affibody" or the "Company"). The nomination committee consists of Malte St Cyr Ohm, nominated by Patricia Industries, Leif Bengtsson nominated by the estate of Ingvar Kamprad and the Company's third largest owner Mathias Uhlén. Malte St Cyr Ohm is the chairman of the nomination committee.

The nomination committee's work

The nomination committee has held one formal meeting and, in addition, has additional interactions via phone and e-mail. The nomination committee has obtained a report from the chairman of the Board of Directors on how the work has been conducted in the Board of Directors and how the work is expected to be conducted in the future.

The nomination committee has also discussed in detail the requirements in terms of diversifications regarding competences, experience and background that may be placed on the Board of Directors of Affibody, taking into account, among other things, the Company's strategic development, governance and control as well as the size, breadth and diversity of competence, international experience, age, gender, background and experience. In addition, independency matters have been taken into account in the nomination committee's discussions, and an assessment has also been made of the capacity of each individual board member to devote sufficient time and commitment to the work of the Board of Directors.

The nomination committee's proposal for the number of members of the Board of Directors to be appointed by the general meeting

The nomination committee proposed that the Board of Directors shall consist of eight members.

The nomination committee's proposal for the Board of Directors

The nomination committee proposes, in addition to the members elected at the annual general meeting, Camilla Sønderby and Anders Martin-Löf are elected as members of the Board of Directors for the period until the end of the next annual general meeting.

Camilla Sønderby

Camilla Sønderby was born in 1972 and is a Danish citizen. Camilla is currently a member of the Board of Directors of F2G Ltd and Healthcare Adviser for EQT Partners. She has more than 20 years' experience from leading positions in international pharmaceutical companies such as Takeda, Shire, Abbott, Roche and Schering Plough. Camilla has substantial experience from commercializing pharmaceuticals, but also from research and development, patient safety matters and IR. Camilla has a degree in Political Science from the University of Copenhagen. Camilla Sønderby is considered independent in relation to Affibody and its senior management and in relation to Affibody's major shareholders.

Anders Martin-Löf

Anders Martin-Löf was born in 1971 and is a Swedish citizen. Anders is currently a member of the Board of Directors of Cantargia AB. Anders has long experience as CFO of companies listed at the Stockholm Stock Exchange and has previously been CFO of Oncopeptides AB, Wilson Therapeutics AB and RaySearch Laboratories AB. He has also been responsible for investor relations and has held various business development positions at Swedish Orphan Biovitrum. Anders has a M.Sc. in Economics and Business from Stockholm University and a M.Sc. in Engineering Physics from the Royal Institute of Technology in Stockholm. Anders Martin-Löf is considered independent in relation to Affibody and its senior management and in relation to Affibody's major shareholders.

Affibody has gone from being a pure research company to a company which has a portfolio of pharmaceutical products under development and a number of commercial collaborations. In light hereof has the nomination committee understood that there is a need to strengthen the Board of Directors further in terms of commercial experience, network and competence from the international pharmaceutical market as well as to strengthen the competence in audit matters within the Board of Directors.

It is the view of the nomination committee that the proposed size and composition of the Board of Directors provides the conditions to monitor, challenge and support the management of the Company regarding strategy formulation and implementation, operations and future development effectively. The nomination committee's proposal for the Board of Directors means that two of eight members are women and that four of eight members have experience from the international pharmaceutical market. The nomination committee strives for diversity in several aspects, primarily gender and international pharmaceutical experience. The desire for a balanced gender distribution and international pharmaceutical experience will be a factor for consideration in connection with the selection of future new Board members.

The nomination committee complies with the Swedish Corporate Governance Code (the "Code"). When assessing the independence of the proposed Board members, the nomination committee has found that the proposed composition of the Board of Directors fulfills the requirements regarding independence set forth in the Code. In relation to the composition of the Board of Directors, the provisions of rule 4.1 of the Code have been applied as diversity policy and with regard to the objectives of that policy, which has resulted in the nomination committee's proposal for the extraordinary general meeting regarding the election of the Board of Directors.

The nomination committee's proposal for directors' fees

The nomination committee proposes that fees to the Board of Directors for the period until the next annual general meeting shall be paid in an amount of SEK 105,000 (corresponding to SEK 250,000 on a full-year basis) to each of the proposed members of the Board of Directors.

In addition, the nomination committee proposes that a fee of SEK 42,000 (corresponding to SEK 100,000 on a full-year basis) shall be paid to the chairman of the audit committee for the period until the next annual general meeting.

The nomination committee's proposal for the election of chairman at the extraordinary general meeting

The nomination committee proposes that attorney-at-law Gunnar Mattsson is elected chairman at the general meeting.